|1.||Lip, Gregory Y H: 47 articles (01/2014 - 07/2002)|
|2.||Blann, A D: 36 articles (10/2014 - 02/2000)|
|3.||Federici, Augusto B: 32 articles (06/2014 - 02/2002)|
|4.||Federici, A B: 31 articles (05/2015 - 01/2000)|
|5.||Castaman, G: 30 articles (05/2014 - 01/2000)|
|6.||Blann, Andrew D: 29 articles (01/2014 - 07/2002)|
|7.||Budde, Ulrich: 28 articles (01/2015 - 04/2002)|
|8.||Mannucci, P M: 26 articles (05/2015 - 01/2000)|
|9.||Budde, U: 25 articles (07/2014 - 01/2000)|
|10.||Favaloro, Emmanuel J: 24 articles (12/2014 - 04/2002)|
|1.||von Willebrand Diseases (von Willebrand's Disease)
01/01/2010 - "The efficacy of highly purified VWF/FVIII concentrates with standardized ristocetin cofactor content (VWF:RCo) has been already proven in patients with von Willebrand's disease (VWD). "
07/01/2007 - "While plasma-derived concentrates containing large amounts of von Willebrand factor (VWF) are effective in treating von Willebrand disease (VWD), optimal dosing remains to be fully characterized. "
01/01/1995 - "The definition of the molecular basis of von Willebrand's disease has helped clarify the structure of von Willebrand factor as well as its essential role in platelet function, particularly under haemodynamic conditions of high shear stress. "
04/01/2011 - "Accelerated clearance of von Willebrand factor (VWF) has been recently identified as a major pathophysiologic mechanism inducing low VWF in some patients with von Willebrand disease (VWD). "
02/01/2006 - "Increased clearance of von Willebrand factor (VWF) is one of the main features of type Vicenza von Willebrand disease (VWD), a variant with plasma and platelet VWF level discrepancies and unusually large VWF multimers. "
11/01/2009 - "For these patients, prophylactic use of concentrates containing von Willebrand factor may help to avoid bleeding events and their associated complications. "
01/01/2013 - "In this proof-of-principle study, we investigated whether alterations in platelet function or von Willebrand factor (vWf) contribute to a bleeding phenotype in these patients. "
07/01/2011 - "An ongoing study, the Zimmerman Program for the Molecular and Clinical Biology of VWD, is currently enrolling patients with all VWD subtypes across the United States to better delineate the extent of VWD and correlate bleeding symptoms with laboratory findings and VWF ( Von Willebrand factor) sequence variations. "
03/01/2011 - "The aim of this study was to assess the Vicenza score's predictive power in identifying type 1 VWD, low von Willebrand factor (VWF) and platelet function defects (PFD) in a prospective cohort of patients, 0-17 years old, referred to a paediatric haematology clinic for evaluation of a bleeding disorder. "
01/01/2009 - "The results of studies involving large cohorts of patients with a wide range of bleeding manifestations and variable von Willebrand factor (VWF) reduction have recently become available. "
01/22/2013 - "In this study, we provide evidence that plaque geometries result in fluid mechanical conditions that promote platelet aggregation and thrombus formation by increased accumulation and activity of von Willebrand factor (vWF) at poststenotic sites. "
06/01/2009 - "More over, in an in vitro study when whole blood was circulated both at venous and arterial shear conditions and shear rate was adjusted according to the blood viscosity, platelet aggregate/thrombus formation was characteristic on surfaces covered with purified von Willebrand factor while in case of controls the surface was covered with single platelets or platelet monolayer. "
07/01/2007 - "The recognition of VWD as a distinct entity in blood and the cloning of the von Willebrand factor (VWF) gene in the 1980s encouraged both phenotypic and genotypic studies, culminating in 1994 with the recognition, by the VWF subcommittee of the Scientific and Standardization Committee (SSC) of International Society of Thrombosis and Haemostasy (ISTH), of three types of VWD, characterized by severe plasma VWF deficiency (type 3), functionally deficient plasma VWF (type 2) and reduced (below normal) levels of plasma VWF, which is functionally essentially normal (type 1; 70% of all cases). "
05/17/2002 - "The purpose of this study was to investigate the antithrombotic effect and bleeding time prolongation of AJW200, a humanized monoclonal antibody to von Willebrand factor (vWF), in a canine model of coronary arterial thrombosis. "
07/01/2015 - "An unbalance between the platelet-adhesive protein von Willebrand factor (VWF) and its cleaving protease ADAMTS13 is a risk factor for thrombosis. "
|4.||Thrombotic Thrombocytopenic Purpura
06/01/2009 - "The active conformation of von Willebrand factor in patients with thrombotic thrombocytopenic purpura in remission."
01/01/1992 - "Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission."
11/04/2010 - "Recent studies demonstrate that Stx also induces von Willebrand factor (VWF) secretion by human endothelial cells and causes thrombotic thrombocytopenic purpura, a disease with similarities to D+HUS, in Adamts13(-/-) mice. "
01/01/2006 - "Recent studies demonstrate that severe deficiency of the von Willebrand factor cleaving metalloprotease, ADAMTS 13, causes thrombotic thrombocytopenic purpura. "
11/30/2005 - "[A study on the significance of plasma thrombospondin1 in thrombotic thrombocytopenic purpura and the relationship between thrombospondin1 and von Willebrand factor cleaving protease (ADAMTS13)]."
|5.||Hemophilia A (Haemophilia)
01/01/1985 - "In addition, these studies suggest that there may be significant differences in the factor VIII-related antigen (VIII R:Ag) on platelets in haemophilia A patients compared to normal."
06/01/2015 - "Evaluation of von Willebrand factor phenotypes and genotypes in Hemophilia A patients with and without identified F8 mutations."
02/01/2015 - "Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?"
08/01/2014 - "Effect of von Willebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review."
07/01/2014 - "The pharmacokinetic profile of rVIII-SingleChain was compared with a marketed full-length recombinant FVIII concentrate (Advate(®)) in haemophilia A mice, von Willebrand factor knock-out mice, Crl:CD (SD) rats, rabbits and cynomolgus monkeys. "
|1.||Factor VIII (Coagulation Factor VIII)
|4.||von Willebrand Factor
|5.||thymidine 5'-triphosphate (TTP)
|6.||Deamino Arginine Vasopressin (Desmopressin)
|8.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|9.||Tissue Plasminogen Activator (Alteplase)
|2.||Homologous Transplantation (Allograft)
|3.||Prostheses and Implants (Prosthesis)